Good morning :)
$
₹
Akari Therapeutics PLC

Akari Therapeutics PLC

AKTX

NASDAQ
Asset Logo

Akari Therapeutics PLC

AKTX

NASDAQ
$7.666.86% (-0.56)
$
₹
$7.666.86% (-0.56)
High
—
—
Low
—
—
Returns
—
—
Loading...
1D
1W
1M
3M
6M
1Y
3Y
5Y
Max

Healthcare

Biotechnology

Micro Cap

With a market cap of $18.8M the stock is ranked 5467

Key Metrics

Key Metrics

PE TTM
PE TTM

Close price divided by the earnings per share for the trailing twelve months

—
PB
PB

Close price divided by the book value per share at the end of the most recent quarter

1.05
EPS TTM
EPS TTM

Net profit earned per share over the trailing twelve months (sum of the last 4 quarters)

$0
PEG Ratio
PEG Ratio

Price-to-Earnings (P/E) ratio divided by the forecasted annual earnings per share (EPS) growth rate over the next five years

0
Profit Margin
Profit Margin

Net profit divided by the total revenue for the most recent financial year

0%
Dividend Yield
Dividend Yield

Annual dividend per share for the trailing twelve months divided by the close price

—

Analyst Ratings & Forecast

Analyst Ratings & Forecast

Detailed Forecast Detailed Forecast 

Based on 3 analysts reports

Buy
3 analysts
Hold
0 analyst
Sell
0 analyst

Price Upside

+210.03%

Earnings Growth

+45.07%

Rev. Growth

—

See Detailed Forecast

Company Profile

Company Profile

Akari Therapeutics, Plc, an oncology company, develops antibody-drug conjugates (ADC) for cancer-killing toxins. Its lead payload is PH1 to disrupt the function of spliceosomes and to trigger an immune response that leads to additional cancer cell killing. The company's lead product candidate is AKTX-101, a preclinical stage trop2-targeting ADC that combines PH1 with the trop2 antibody to treat solid tumor cancer types, including lung, breast, bladder, head and neck, gastric, pancreatic, colon, prostate, and others. Its payloads include PH1 is a novel payload that is a spliceosome modulator designed to disrupt RNA splicing within cancer cells. The company also develops AKTX-102, a novel bispecific ADC that utilizes PH1 as its payload to treat various solid tumor cancers. Akari Therapeutics, Plc is headquartered in Tampa, Florida.
Akari Therapeutics, Plc, an oncology company, develops antibody-drug conjugates (ADC) for cancer-killing toxins. Its lead payload is PH1 to disrupt the function of spliceosomes and to trigger an immune response that leads to additional cancer cell killing. The company's lead product candidate is AKTX-101, a preclinical stage trop2-targeting ADC that combines PH1 with the trop2 antibody to treat solid tumor cancer types, including lung, breast, bladder, head and neck, gastric, pancreatic, colon, prostate, and others. Its payloads include PH1 is a novel payload that is a spliceosome modulator designed to disrupt RNA splicing within cancer cells. The company also develops AKTX-102, a novel bispecific ADC that utilizes PH1 as its payload to treat various solid tumor cancers. Akari Therapeutics, Plc is headquartered in Tampa, Florida.

Peers

Compare with peers Compare with peers 

Peers

Compare with peers Compare with peers 
Eli Lilly and Company
LLY
Eli Lilly and Company
P/E Ratio
42.74
42.74
1Y Return
55.33%
55.33%
Buy Reco %
83.87
83.87
Johnson & Johnson
JNJ
Johnson & Johnson
P/E Ratio
40.03
40.03
1Y Return
37.93%
37.93%
Buy Reco %
69.56
69.56
Merck & Company Inc
MRK
Merck & Company Inc
P/E Ratio
115.29
115.29
1Y Return
66.63%
66.63%
Buy Reco %
70.37
70.37
Novartis AG ADR
NVS
Novartis AG ADR
P/E Ratio
22.82
22.82
1Y Return
14.79%
14.79%
Buy Reco %
41.66
41.66
AstraZeneca PLC
AZN
AstraZeneca PLC
P/E Ratio
25.78
25.78
1Y Return
1.93%
1.93%
Buy Reco %
83.33
83.33
Compare with Peers

Forecast

Forecast

Price

Revenue

Earnings

Price Forecast

Price Forecast

Higher price growth forecast versus trailing 3-year CAGR
Compares analyst forecast growth with historical annualized growth.

The 12-month consensus target implies 210.03% growth, versus a trailing 3-year CAGR of 33.85%.

2026
Current$8.22Baseline
Analyst Target - 1 year
Target$25.5+210.03%

All values in $

202220232024202520262027$7.21$14.16$21.10Target+210.03%
2026
Current$8.22Baseline
Analyst Target - 1 year
Target$25.5+210.03%

All values in $

Earnings Per Share Forecast

Earnings Per Share Forecast

2025
Current$-16.47Baseline
Forecast for Dec 2026
High$-9.05+45.07%
Average$-9.05+45.07%
Low$-9.05+45.07%

All values in $

20202021202220252026N/AN/A-2.62-16.47Low+45.07%Average+45.07%High+45.07%
2025
Current$-16.47Baseline
Forecast for Dec 2026
High$-9.05+45.07%
Average$-9.05+45.07%
Low$-9.05+45.07%

All values in $

Financials

Financials

Income

Balance Sheet

Cash Flow

-6.4
-5.2
-14.4
-4.8
Q3 2025
Q4 2025
Q1 2026
Q2 2026
Revenue
Net Income
Financial YearQ1 2024Q2 2024Q3 2024Q4 2024Q1 2025Q2 2025Q3 2025Q4 2025Q1 2026Q2 2026
Total Revenue00000.0200000
Net Income-5.56-7.55-2.89-3.77-3.70-1.89-6.4-5.29-14.45-4.80
Net Profit Margin-----14251.09%-----
See CostsAll values in $ Million

Peers

Peers & Comparison

Peers & Comparison

Comparing 2 stocks from
HealthcareBiotechnology

Valuation

Returns

Forecast

ScreenerCompare valuation on Screener
StockPE TTMPE TTMPBPBPEG RatioPEG Ratio
Akari Therapeutics PLC -1.050
Eli Lilly and Company42.7430.781.15
Johnson & Johnson40.037.632.82
ScreenerCompare valuation on Screener

Price Comparison

Price Comparison

Compare AKTX with any stock or ETF
Compare AKTX with any stock or ETF
Comparing from
AKTX
LLY
JNJ
Loading...

Frequently asked questions

  1. Akari Therapeutics PLC (AKTX) share price today is $7.66 as of October 27, 2026 at 1:26 AM IST. The stock touched a day high of $8.63 and a day low of $7.66.

  2. Akari Therapeutics PLC stock trades on NASDAQ under the ticker symbol AKTX.

  3. Akari Therapeutics PLC's market capitalization is $18.79M as of October 27, 2026 at 1:26 AM IST.

  4. Akari Therapeutics PLC's price-to-earnings (P/E) ratio is N/A as of October 26, 2026.

  5. Akari Therapeutics PLC's price-to-book (P/B) ratio is 1.05 as of October 26, 2026.

  6. Yes, You can buy Akari Therapeutics PLC shares from India through Tickertape, via our partnership with ViewTrade IFSC under the IFSCA Global Access framework, subject to RBI’s Liberalised Remittance Scheme (LRS) limits.

  7. Indian investors can buy Akari Therapeutics PLC shares in three steps: 1. Search Akari Therapeutics PLC on the Tickertape app and tap Invest. 2. Complete your one-time digital KYC. 3. Fund your account and buy from as low as $1 via fractional shares.

  8. Since Akari Therapeutics PLC trades in USD, an Indian investor's INR returns depend on both the stock's price movement and the USD-INR exchange rate. If the rupee depreciates against the dollar, INR returns are boosted beyond the stock's USD return; if the rupee appreciates, INR returns are reduced.

  9. Indian investors can start investing in Akari Therapeutics PLC (AKTX) shares from as little as $1 through fractional ownership on Tickertape - for example, $10 buys approximately 1.3054 shares at the current price of $7.66.

Loading...